1. Confirmed HER2 negative;

2. Has tumor-related medical history or treatment history;

3. Has severe combined disease/medical history and treatment history;

4. Has received treatment with systemic immunostimulants or immunosuppressants;

5. Be allergic to the test drug;

6. Participate in other clinical trials simultaneously;

7. Has received vaccine within 30 days before the first dose;

8. Has received allograft bone marrow transplantation;

9. Has given birth within one year or is breastfeeding;

10. Has history of psychological drug abuse, alcoholism or drug use.

A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer